Klin Farmakol Farm. 2021;35(1):40-42 | DOI: 10.36290/far.2021.007

A Case of Ceftriaxone‑Induced Biliary Pseudolithiasis

Timea Taschová1, Martin Zápalka2, Kamila Michálková3, Karel Urbánek1
1 Ústav farmakologie LF UP a FN Olomouc
2 Dětská klinika LF UP a FN Olomouc
3 Radiologická klinika LF UP a FN Olomouc

The report presents a case of a 13-year-old boy treated for Borrelia meningitis with i.v. ceftriaxone at a dose of 50 mg/kg. On the fifth day of therapy, abdominal pain occurred and the presence of concrements in the gallbladder was proven by ultrasonography. The symptoms resolved within one day and the subsequent ultrasound findings after 3 months with ursodeoxycholic acid treatment was completely normal. The cause of the symptoms was ceftriaxone-induced pseudolithiasis due to the precipitation of the antibiotic at very high concentrations in the gallbladder with calcium.

Keywords: ceftriaxone, adverse effects, biliary pseudolithiasis, pediatrics.

Published: April 9, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Taschová T, Zápalka M, Michálková K, Urbánek K. A Case of Ceftriaxone‑Induced Biliary Pseudolithiasis. Klin Farmakol Farm. 2021;35(1):40-42. doi: 10.36290/far.2021.007.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Beneš J. Antibiotika: systematika, vlastnosti, použití. Praha: Grada Publishing, a. s., 2018: 600 s.
    2. Pacifici GM. Clinical pharmacology of ceftriaxone in infants and children. J Target Drug Deliv 2019; 3(1): 1-13. Go to original source...
    3. Schaad UB, Wedgwood‑Krucko J, Tschaeppeler H. Reversible ceftriaxone‑associated biliary pseudolithiasis in children. Lancet. 1988 Dec 17; 2(8625): 1411-1413. Go to original source... Go to PubMed...
    4. Alemayehu H, Desai AA, Thomas P, Sharp SW, St Peter SD. Ceftriaxone‑induced pseudolithiasis in children treated for perforated appendicitis. Pediatr Surg Int. 2014 Mar; 30(3): 323-326. Go to original source... Go to PubMed...
    5. Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone‑associated biliary sludge. In vitro studies of calcium‑ceftriaxone binding and solubility. Gastroenterology. 1990 Dec; 99(6): 1772-1778. Go to original source... Go to PubMed...
    6. Imafuku A, Sawa N, Sekine A, Kawada M, Hiramatsu R, et al. Risk factors of ceftriaxone‑associated biliary pseudolithiasis in adults: influence of renal dysfunction. Clin Exp Nephrol. 2018 Jun; 22(3): 613-619. Go to original source... Go to PubMed...
    7. Fretzayas A, Liapi O, Papadopoulou A, Nicolaidou P, Stamoulakatou A. Is Ceftriaxone‑induced biliary pseudolithiasis influenced by UDP‑glucuronosyltransferase 1A1 gene polymorphisms? Case Rep Med. 2011; 2011: 730250. Go to original source... Go to PubMed...
    8. Kato Y, Takahara S, Kato S, Kubo Y, Sai Y, Tamai I, Yabuuchi H, Tsuji A. Involvement of multidrug resistance‑associated protein 2 (Abcc2) in molecular weight‑dependent biliary excretion of beta‑lactam antibiotics. Drug Metab Dispos. 2008 Jun; 36(6): 1088-1096. Go to original source... Go to PubMed...
    9. de Moor RA, Egberts AC, Schröder CH. Ceftriaxone‑associated nephrolithiasis and biliary pseudolithiasis. Eur J Pediatr. 1999 Dec; 158(12): 975-977. Go to original source... Go to PubMed...
    10. Oggiano AM, Clemente MG, Cuzzolin L, Locci C, Piredda CM, Schwarz KB, Antonucci R. Pharmacological treatment of ceftriaxone‑related cholelithiasis in children: is it worthwhile? Journal of Pediatric and Neonatal Individualized Medicine 2019; 8(1): e080108.
    11. Cuzzolin L, Oggiano AM, Clemente MG, Locci C, Antonucci L, Antonucci R. Ceftriaxone‑associated biliary pseudolithiasis in children: do we know enough? Fundam Clin Pharmacol. 2021 Feb; 35(1): 40-52. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.